SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Herantis Extends HER-096 Phase 2 Treatment Period to Nine Months

Herantis Pharma extended the placebo-controlled treatment period for its HER-096 Phase 2 study to nine months.

Related stories